The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...

WHIM syndrome (characterized by warts, hypogammaglobulinemia, infections, and myelokathexis) is a rare immunodeficiency caused by inherited autosomal-dominant mutations in CXCR4 that confer gain ...

Cytokine CXCL12 (also known as stromal-derived factor 1α) and its receptor CXCR4 represent the most promising actionable targets for this strategy. Both are overexpressed in various cancer types ...

Despite the fact that HIV is a multifactorial disease, research has shown that specific targetingof CXCR4 and CCR5 is a potential therapeutic tactic for HIV as well as other immune situations like ...

StudyPentixapharm Holding AG: Pentixapharm outlines new clinical development strategy 27-May-2025 / 09:43 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No ...

Dr. Susan Schwab and her lab at the NYU Langone Medical Center have associated CXCR4 signaling as a positive regulator of T-cell acute lymphoblastic leukemia (T-ALL) growth and disease progression.

We assessed safety and efficacy, as well as the influence of MYD88 and CXCR4 mutations on responses, in patients who had received previous treatment for Waldenström’s macroglobulinemia.

Phase II study of temozolomide as maintenance therapy after disease control of the first-line induction therapy in small cell lung cancer. Bone metastases in patients with small cell lung carcinoma: ...

Using their novel approach, the scientists were able to disable a protein on the T-cell surface called CXCR4, which can be exploited by HIV when the virus infects T cells and causes AIDS.

Pentixapharm’s current therapeutic pipeline consists solely of PentixaTher, a CXCR4 cytokine receptor in a phase 1/2 trial for patients with lymphoma affecting the central nervous system.